SBI Term Loan: RLLR: 8.15 | 7.25% - 8.55%
Canara Bank: RLLR: 8 | 7.15% - 9.85%
ICICI Bank: RLLR: -- | 8.5% - 9.65%
Punjab & Sind Bank: RLLR: 7.3 | 7.35% - 10.75%
Bank of Baroda: RLLR: 7.9 | 7.2% - 8.95%
Federal Bank: RLLR: -- | 7.35% - 9.6%
IndusInd Bank: RLLR: -- | 7.6% - 10%
Bank of Maharashtra: RLLR: 8.05 | 7% - 9.15%
Yes Bank: RLLR: -- | 7.4% - 10.54%
Karur Vysya Bank: RLLR: 8.8 | 8.5% - 10.65%
HDFC Bank: RLLR: -- | 7.75% - 13.2%
Axis Bank: RLLR: -- | 8% - 9.1%
IDBI Bank: RLLR: -- | 7.4% - 10%

Tavexia Lifecare proposes acquisition of 60% stake in Meyonex Pharmaceuticals

#Hospitality & Retail#Industrial#India
Synopsis

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, has proposed acquiring up to 60% of Meyonex Pharmaceuticals Limited, an unlisted pharmaceutical manufacturing company based in Tarapur, Palghar, Maharashtra. The proposal was considered by Tavexia's Board at its September 7, 2026 meeting and remains subject to due diligence, valuation, negotiations and definitive agreements. The company is evaluating expansion across pharmaceuticals, active pharmaceutical ingredients and intermediates, specialty chemicals, nutraceuticals, biotechnology, and contract research and manufacturing. Separately, Tavexia has appointed DEVAM & Associates LLP as its proposed new statutory auditor for FY 2026-27 to FY 2030-31, subject to shareholder approval, following the resignation of SSRV and Associates. The Board has also approved the proposed second five-year term of Independent Director Khushboo Vasudev, effective December 31, 2026, subject to shareholder approval.

Tavexia Lifecare Limited has proposed acquiring up to 60% of Meyonex Pharmaceuticals Limited as part of its planned expansion into pharmaceutical manufacturing, following decisions taken by its Board of Directors at a meeting held on September 7, 2026. Meyonex is an unlisted pharmaceutical manufacturing company based in Tarapur, Palghar, Maharashtra. 
The Board has authorised Chirag Deepak Dedhia and Sachin Bhanubhai Manseta, Directors of Tavexia, to lead preliminary discussions with Meyonex. Their responsibilities will include due diligence, valuation and negotiations relating to the proposed transaction. 
The acquisition is not yet finalised. Tavexia said the proposal remains subject to satisfactory due diligence, valuation and negotiations, followed by the execution of definitive agreements. 
The proposed investment forms part of Tavexia's broader strategic transition towards the pharmaceutical, chemicals and lifecare sectors. The company is evaluating opportunities across pharmaceutical products, active pharmaceutical ingredients (APIs) and intermediates, specialty chemicals, nutraceuticals, biotechnology, and contract research and manufacturing. 
According to the company, the broader strategy is intended to develop a diversified business platform and expand its operating capabilities and addressable market. The proposed Meyonex transaction would be considered within this wider expansion plan, with Tavexia evaluating opportunities to establish additional manufacturing capabilities and build its presence in pharmaceuticals. 
Alongside the proposed acquisition, Tavexia has made changes to its statutory audit arrangements. M/s SSRV and Associates, Chartered Accountants, resigned as the company's Statutory Auditors with effect from September 7, 2026, citing preoccupation with other professional commitments. The firm stated that it had not communicated any reportable concerns to the Audit Committee or Board before its resignation. 
The Board subsequently approved the appointment of M/s DEVAM & Associates LLP, Chartered Accountants, as the new Statutory Auditors, subject to shareholder approval. The proposed appointment covers a first term of five consecutive years, from FY 2026-27 to FY 2030-31. 
The Board has also approved the re-appointment of Khushboo Vasudev as an Independent Director for a second five-year term beginning December 31, 2026, subject to shareholder approval. The company said Vasudev has more than 10 years of experience in corporate law, corporate management and compliance, and that her continued association is intended to support governance, strategic oversight and decision-making. 
Tavexia, a listed company, said it would continue evaluating opportunities across pharmaceuticals, APIs and intermediates, specialty chemicals, nutraceuticals, biotechnology and contract research and manufacturing. The company will also keep shareholders and stock exchanges informed of material developments in accordance with applicable regulatory requirements.

Discussion

Have something to say? Post your comment